Background: Randomised phase III clinical trials represent a methodological milestone to select effective drugs against metastatic cancers. In this context, and particularly in the efficacy assessment of biologic drugs, the initial metastatic tumour burden is a strong prognostic factor. Methods: A systematic literature review of randomised, phase III, first-line, clinical trials in metastatic breast, colorectal, and lung cancers, published from 2016 to 2021, was performed. Three groups of variables were collected: identity-, method-(including tumour burden assessment) and outcome-related. Results: Seventy trials were selected. A large portion of studies (41.4%) focused on the effects of biologic agents (signal inhibitors and immuno-therapie...
The results of individual phase III cancer clinical trials are often inconclusive due to the overly ...
The aim of this thesis was to understand and improve the design of clinical trials testing targeted ...
BACKGROUND: The role of tumor mutational burden (TMB) is still debated for selecting advanced non-on...
Background: Randomised phase III clinical trials represent a methodological milestone to select effe...
Purpose: The demand for more rapid access to novel biologic therapies than randomized controlled tr...
Background: Oligometastatic disease (OMD) identifies tumours with limited metastatic spread. OMD def...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
INTRODUCTION: In- and exclusion criteria of randomized clinical trials (RCTs) aim to include a homog...
BACKGROUND: In this study, we compared and contrasted design characteristics, results, and publicati...
Abstract: Breast cancer remains the most common cause of cancer death among women. Despite its consi...
Current lung cancer clinical research focuses on biomarkers and personalized treatment strategies. A...
A distinctive subset of metastatic breast cancer (MBC) is oligometastatic disease, which is characte...
(1) Background: Drug development in oncology is changing rapidly. The aim of the present study was t...
Background: Oligometastatic disease (OMD) identifies tumours with limited metastatic spread. OMD def...
This article reports on recent advances on metastatic breast cancer. Detection, prognostic factors, ...
The results of individual phase III cancer clinical trials are often inconclusive due to the overly ...
The aim of this thesis was to understand and improve the design of clinical trials testing targeted ...
BACKGROUND: The role of tumor mutational burden (TMB) is still debated for selecting advanced non-on...
Background: Randomised phase III clinical trials represent a methodological milestone to select effe...
Purpose: The demand for more rapid access to novel biologic therapies than randomized controlled tr...
Background: Oligometastatic disease (OMD) identifies tumours with limited metastatic spread. OMD def...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
INTRODUCTION: In- and exclusion criteria of randomized clinical trials (RCTs) aim to include a homog...
BACKGROUND: In this study, we compared and contrasted design characteristics, results, and publicati...
Abstract: Breast cancer remains the most common cause of cancer death among women. Despite its consi...
Current lung cancer clinical research focuses on biomarkers and personalized treatment strategies. A...
A distinctive subset of metastatic breast cancer (MBC) is oligometastatic disease, which is characte...
(1) Background: Drug development in oncology is changing rapidly. The aim of the present study was t...
Background: Oligometastatic disease (OMD) identifies tumours with limited metastatic spread. OMD def...
This article reports on recent advances on metastatic breast cancer. Detection, prognostic factors, ...
The results of individual phase III cancer clinical trials are often inconclusive due to the overly ...
The aim of this thesis was to understand and improve the design of clinical trials testing targeted ...
BACKGROUND: The role of tumor mutational burden (TMB) is still debated for selecting advanced non-on...